The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are druggable, is the best starting point for improved productivity.
The seven chapters of this volume describe recent progress towards drugs acting at a range of druggable targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.
*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect

Hardbound. This volume reviews recent advances in five important areas of medicinal chemistry which will be of interest both to chemists and to scientists of other disciplines engaged in medicines research and development. Included are accounts of successful drug discovery programmes, disease targets of unmet medical need, and recent progress in new technologies which are considered by many to hold the key to future developments in medicinal chemistry.The style and organisation of chapters follow a similar pattern to previous volumes but references, where appropriate, now include website addresses of the World Wide Web.

The Progress in Medicinal Chemistry series spans a wide range of topics of interest to the drug discovery community. This particular volume touches upon the following:
* The Herg ion channel
* Fluorescence-based high throughput assay
* Aprepitant and neurokinin receptors
* Muscarinic receptor targets
* Gene activation pathways
* Malaria and antimalarial drugs
* HIV virus mutation and new therapeutics
Progress in Medicinal Chemistry is available online on ScienceDirect - full-text online of volumes 41 onwards.

Elsevier book series on ScienceDirect gives multiple users throughout an institution simultaneous online access to an important compliment to primary research. Digital delivery ensures users reliable, 24-hour access to the latest peer-reviewed content. The Elsevier book series are compiled and written by the most highly regarded authors in their fields and are selected from across the globe using Elsevier's extensive researcher network.

For more information about the Elsevier Book Series on ScienceDirect Program, please visit:
http: //www.info.sciencedirect.com/bookseries/
*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect

This volume includes information on recent advances in five important areas: an account of inhibitors of the caspase family of proteolytic enzymes that represent a new class of anti-inflammatory and antiapoptotic agents of potential value in rheumatoid arthritis; and a survey of semi-synthetic and totally synthetic antibiotics and anti-HIV agents and their sites of interaction; the development of inhibitors of the intracellular enzyme acyl-CoA: cholesterol O-acyltransferase (ACAT) for the treatment of hypercholesterolemia; a description of recent progress in growth hormone secretagogues, with the focus on strategies to improve oral bioavailability and duration of action; and information on inhibition of the proteolytic enzyme, hepatitis C protease N-3(NS3), (required for vital replication) as one of the most attractive targets for HCV infections.

The Progress in Medicinal Chemistry series is a respected and instructive source of information on the subject. It has a long established reputation for excellent coverage of almost every facet of medicinal chemistry. This volume includes information on the discovery and development of Atorvastatin; the discovery of CEP-1347/KT-7515, an JNK/SAPK pathway for the treatment of neurodegenerative diseases such; and the discovery of second generation Quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1; and molecular modeling of Opioid receptor-Ligand complexes.

This volume covers contemporary advances in five important areas of pharmacology and medicinal chemistry including: a comprehensive account of inhibitors of the caspase family of proteolytic enzymes that represent a new class of anti-inflammatory and antiapoptotic agents of potential value in rheumatoid arthritis, and other peripheral and central indications; adoc umented survey of semi-synthetic and totally synthetic antibiotics and anti HIV agents and their sites of interaction; inhibitors of the intracellular enzyme acyl-CoA: cholesterol O-acyltransferase (ACAT) developed for the treatment of hypercholesterolemia; and recent progress in growth hormone secretagogues, with the focus on strategies to improve oral bioavailability and duration of action. Inhibition of the proteolytic enzyme, hepatitis C protease N-3(NS3), required for viral replication, is one of the most attractive targets for HCV infections. Progress and prospects in the design of peptide and non-peptide inhibitors are described here. design and clinical potential of new drug molecules; valuable summaries of structure-activity relationships in topical areas of medicinal chemistry; and extensive references to the biology, medicinal chemistry and clinical aspects of each topic.

The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a quality lead, where these quality leads come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.
*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect